Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Refractory or Recurrent Multiple Myeloma

NCT00079716 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT00079716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00079716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Refractory or Recurrent Multiple Myeloma
Lead sponsor
Seagen Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2004
Completion date
November 30, 2007
Enrollment
44 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma